Previous 10 | Next 10 |
PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results PR Newswire SOUTH PLAINFIELD, N.J. , Feb. 15, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast c...
2024-02-12 16:46:59 ET More on Biogen Biotech And Pharma Diversification Pays Off Biogen Inc. (BIIB) JPMorgan 42nd Annual Healthcare Conference (Transcript) Biogen: LEQEMBI's $10 Billion Potential Biogen Q4 2023 Earnings Preview Biogen scraps Aduhelm,...
2024-02-11 18:00:00 ET Summary PTC Therapeutics has a diverse portfolio and pipeline of drugs, including a broader DMD treatment. The company has not fully expanded its revenue-generating products geographically and is in the process of making the necessary submissions to do so. ...
2024-01-31 00:21:00 ET Summary Q4 marks the end of a difficult year for Russell 2000 earnings. Energy is no longer the 'top dog' from an earnings growth contribution perspective. Financials has the largest earnings weight for the second consecutive quarter. By Taji...
2024-01-25 17:30:32 ET More on PTC Therapeutics PTC Therapeutics, Inc. (PTCT) Q3 2023 Earnings Call Transcript PTC Therapeutics says total unaudited FY23 net revenue was about $946M PTC Therapeutics issues EU, US regulatory updates on Translarna Seeking Alpha...
2024-01-25 16:59:42 ET Gainers: Ocular Therapeutix, ( OCUL ) +5% . AppFolio ( APPF ) +4% . Sagimet Biosciences ( SGMT ) +3% . Xcel Energy ( XEL ) +3% . Digital World Acquisition ( DWAC ) +2% . Losers...
CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarna™ (ataluren) Following Re-examination Procedure PR Newswire SOUTH PLAINFIELD, N.J. , Jan. 25, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) anno...
2024-01-08 11:40:25 ET More on PTC Therapeutics PTC Therapeutics issues EU, US regulatory updates on Translarna PTC Therapeutics stock slides after Citi downgrades to Sell Seeking Alpha’s Quant Rating on PTC Therapeutics Historical earnings data for PT...
PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 42nd Annual J.P. Morgan Healthcare Conference PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 42nd Annual J.P. Morgan Healthcare Conference PR Newswire ...
PTC Therapeutics to Participate at 42nd Annual J.P. Morgan Healthcare Conference PR Newswire SOUTH PLAINFIELD, N.J. , Jan. 3, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the 42 n...
News, Short Squeeze, Breakout and More Instantly...
PTC Therapeutics Inc. Company Name:
PTCT Stock Symbol:
NASDAQ Market:
PTC Therapeutics Inc. Website:
PTC Therapeutics Announces Sepiapterin NDA Submission to FDA PR Newswire WARREN, N.J. , July 30, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the submission of the sepiapterin NDA to the U.S. FDA. The NDA submission is for the t...
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2024 Financial Results PR Newswire WARREN, N.J. , July 25, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to r...
2024-07-12 10:00:03 ET Jeffrey Hung from Morgan Stanley issued a price target of $32.00 for PTCT on 2024-07-12 08:15:00. The adjusted price target was set to $32.00. At the time of the announcement, PTCT was trading at $33.2. The overall price target consensus is at $43....